Novartis: Polycythemia Vera trials

The registry lists 12 Polycythemia Vera studies with Novartis as lead sponsor. 1 are open to participants now and 3 have results posted.

Phase 1 2Phase 2 1Phase 3 2Phase 4 2No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Managed Access Programs for INC424, RuxolitinibAvailableNCT04745637
• Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.CompletedNCT02292446Phase 3Results posted
• Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.CompletedNCT02038036Phase 3Results posted
• A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MFCompletedNCT01787552Phase 1/2Results posted
• A Study of Real-world Use and Effectiveness of Cytoreductive Strategies for the Treatment of Second-line Polycythemia Vera in FranceCompletedNCT07839858
• Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM PredictorsTerminatedNCT05853458Phase 4
• A Prospective, Non-interventional Study of JAKAVI® (Ruxolitinib) Treatment in Patients With Polycythemia VeraCompletedNCT05853445
• Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia VeraActive, not recruitingNCT05548062
• Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea.CompletedNCT05421104
• MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia VeraNo longer availableNCT05269771
• Study of Select Combinations in Adults With MyelofibrosisWithdrawnNCT04283526Phase 1
• CINC424A2X01B Rollover ProtocolActive, not recruitingNCT02386800Phase 4